Nanomedicine: Nanotechnology, Biology and Medicine
Volume 5, Issue 2 , Pages 184-191, June 2009

Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery

  • Rishi Paliwal, MPharm

      Affiliations

    • Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr. H.S. Gour Vishwavidyalaya, Sagar, India
  • ,
  • Shivani Rai, MPharm

      Affiliations

    • Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr. H.S. Gour Vishwavidyalaya, Sagar, India
  • ,
  • Bhuvaneshwar Vaidya, MPharm

      Affiliations

    • Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr. H.S. Gour Vishwavidyalaya, Sagar, India
  • ,
  • Kapil Khatri, MPharm

      Affiliations

    • Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr. H.S. Gour Vishwavidyalaya, Sagar, India
  • ,
  • Amit K. Goyal, MPharm

      Affiliations

    • Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr. H.S. Gour Vishwavidyalaya, Sagar, India
  • ,
  • Neeraj Mishra, MPharm

      Affiliations

    • Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr. H.S. Gour Vishwavidyalaya, Sagar, India
  • ,
  • Abhinav Mehta, MPharm

      Affiliations

    • Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr. H.S. Gour Vishwavidyalaya, Sagar, India
  • ,
  • Suresh P. Vyas, PhD

      Affiliations

    • Nanomedicine Research Centre, ISF College of Pharmacy, Moga, Punjab, India
    • Corresponding Author InformationCorresponding author.

Received 12 August 2007; accepted 24 August 2008. published online 17 December 2008.

Abstract 

Solid lipid nanoparticles (SLNs) are essentially composed of triglyceride(s) that orient to form a polar core with polar heads oriented toward the aqueous phase, resembling chylomicrons. The composition of such SLNs may alter the course of drug absorption predominantly to and through lymphatic route and regions, presumably following a transcellular path of lipid absorption, especially by enterocytes and polar epithelial cells of the intestine. SLNs were prepared using stearic acid, glycerol monostearate, tristearin, and Compritol 888 ATO by solvent diffusion method using demineralized double-distilled water as the dispersion medium. The SLNs were characterized for shape, size, zeta potential, and percentage drug content and its release. The characterization of SLNs suggests that Compritol 888 ATO–based nanoparticles were heterogeneous with better drug-loading and release characteristics as compared with the other formulations. The selected products were studied for in vivo absorption and hence bioavailability by measure of area under the blood plasma curve plotted as a function of time. Periodic lymphatic concentration of drug following oral administration of respective formulations was also determined by mesenteric duct cannulation and collection of samples. The comparative study conducted on methotrexate (MTX)-bearing SLNs revealed that the formulation based on Compritol 888 ATO could noticeably improve the oral bioavailability of MTX, presumably following SLNs constituting lipid digestion and co-absorption through lymphatic transport and route.

Key words: Solid lipid nanoparticles, Lipid-based carrier systems, Intestinal lymphatics, Methotrexate

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Financial support by the University Grants Commission (UGC), New Delhi, INDIA, as JRF to one of the authors (Rishi Paliwal) is duly acknowledged.

PII: S1549-9634(08)00146-9

doi:10.1016/j.nano.2008.08.003

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 5, Issue 2 , Pages 184-191, June 2009